As noted above, the RALES and other clinical trials investigated the benefits for MRA as add on therapy to current best practice therapy and demonstrated a role for MR signaling in all-cause heart failure, heart failure post-MI and in mild heart failure (Pitt et al., 1999, 2003; Zannad et al., 2010). This evidence concerns the gene NR3C2 and heart failure.